AUSTRALIAN ASSOCIATED PRESS
  • TRUSTED
  • ACCURATE
  • IMPARTIAL
DONATE SUBSCRIBE

Pierre Fabre Laboratories announces the submission by Atara Biotherapeutics of Tabelecleucel (Tab-cel®) Biologics License Application for treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S FDA

PRNewswire May 20, 2024
  • First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug Administration 
  • The BLA is supported by data from the pivotal Phase 3 ALLELE study which was investigating Tab-cel in relapsed or refractory EBV+ PTLD following solid organ transplant (SOT) or hematopoietic cell transplant (HCT)
  • If Approved, Tab-cel Would be the First Approved Therapy in U.S. for EBV+ PTLD and will be commercialized in the US by the newly established subsidiary Pierre Fabre Pharmaceuticals Inc. 

CASTRES, France, May 20, 2024 /PRNewswire/ — Pierre Fabre Laboratories today announce the submission by Atara Biotherapeutics (ATARA), a leader in T-cell immunotherapies, of Tabelecleucel (Tab-cel®) Biologics License Application for treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S Food and Drug Administration (FDA), indicated as monotherapy for treatment of adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy. For solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate. There are no FDA approved therapies in this treatment setting.

“Patients facing relapsed or refractory EBV+ PTLD have limited therapeutic options and their survival is unfortunately often measured in weeks or months. Filing of the BLA is a significant step towards making  Tab-cel® available to patients in the United States. We congratulate our partner ATARA on this significant achievement and are now focused on preparing for the potential FDA review and approval” said Adriana Herrera, Chief Executive Officer of Pierre Fabre Pharmaceuticals Inc., the new Pierre Fabre Medical Care subsidiary in the United States.

For more information, visit www.pierre-fabre.com, @PierreFabreGroup. 

Pierre Fabre Laboratories Media Contact:

Laurence Marchal, Laurence.marchal@pierre-fabre.com

PDF – https://mma.prnewswire.com/media/2416807/Pierre_Fabre_PDF.pdf

Pierre Fabre Laboratories

SOURCE Pierre Fabre

Keep updated

Latest Releases

Latest News

AAPR aggregates press releases and media statements from around the world to assist our news partners with identifying and creating timely and relevant news.

All of the press releases published on this website are third-party content and AAP was not involved in the creation of it. Read the full terms.

AAP FactCheck

  • Information you can trust
  • Written by trained, experienced journalists using authoritative sources
  • Accredited by the International Fact-Checking Network (IFCN)

AAP FactCheck provides factual, authoritative information Australians can rely on. Accredited with the Poynter Institute's International Fact-Checking Network and adhering to the highest industry standards, our experienced team works to minimise the impact of misinformation.

AAP Photos

  • Award-winning Australian Photography
  • Editorial or Commercial use
  • Subscriptions or one-off licences

Image buyers from all industries rely on AAP Photos. A digital treasure trove of content depicting Australian life, our fully-searchable database contains millions of images from around the country and around the world.

AAPNews

  • News delivered to your inbox
  • Trusted, reliable and accurate
  • Corporate and individual packages available

AAPNews delivers newswire content direct to the public. Choose from a number of subscription models to not only gain access to high-quality fact-based news on your desktop or mobile device, but also to show your support for Australia's only not-for-profit newswire.

Newsroom

  • The wire – up to the minute news at your fingertips
  • Feeds delivered to your CMS
  • Agenda – AAP’s planning and events tool

Get the news feed your organisation needs, with AAP offering extensive coverage of news, courts, politics, sports, finance and the arts. Take advantage of AAP’s partner content to get the international news that matters to your business, with news feeds delivered via multiple channels including API and FTP.